Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Selenium Cancer Risk Reduction Qualified Claims To Be Allowed By FDA

This article was originally published in The Tan Sheet

Executive Summary

Health claims linking selenium supplements with reducing cancer risk will be permitted by FDA through its "enforcement discretion," according to the agency

You may also be interested in...



Phosphatidylserine Data Limited To Dementia Mitigation Not Prevention – FDA

All the data submitted to FDA in support of a health claim linking phosphatidylserine to prevention of dementia or cognitive dysfunction examine the ingredient's ability to mitigate the conditions in a diseased population, not on reducing risk in the general population, the agency said in a May 13 letter

Phosphatidylserine Data Limited To Dementia Mitigation Not Prevention – FDA

All the data submitted to FDA in support of a health claim linking phosphatidylserine to prevention of dementia or cognitive dysfunction examine the ingredient's ability to mitigate the conditions in a diseased population, not on reducing risk in the general population, the agency said in a May 13 letter

Phosphatidylserine Data Limited To Dementia Mitigation Not Prevention – FDA

All the data submitted to FDA in support of a health claim linking phosphatidylserine to prevention of dementia or cognitive dysfunction examine the ingredient's ability to mitigate the conditions in a diseased population, not on reducing risk in the general population, the agency said in a May 13 letter

Related Content

Topics

UsernamePublicRestriction

Register

OM011381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel